Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing InnoCare Plans Combined Therapy with Arrivent for NSCLC

publication date: Jul 14, 2023

Beijing InnoCare Pharma forged a clinical development collaboration with ArriVent, a Philadelphia area biopharma, to test a combination drug regimen for advanced non-small cell lung cancer. The trial will evaluate a combination of InnoCare’s novel SHP2 allosteric inhibitor, ICP-189, with ArriVent’ s furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor. InnoCare’s ICP-189 SHP2 mediates the MAPK signaling pathway and immune checkpoint pathway. In preclinical tests, it has shown better selectivity than other phosphatases, demonstrating significant anti-tumor effects in several xenograft models, InnoCare says. More details....

Stock Symbols: (HK: 09969; SHA: 688428)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital